Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (Nasdaq: BBIO) is set to host a webcast on March 22 at 8:00 a.m. ET, to discuss early results from a Phase 2 proof-of-concept study of encaleret for treating Autosomal Dominant Hypocalcemia Type 1 (ADH1). The data will also be presented at the ENDO 2021 conference. If successful, encaleret could be the first approved therapy for ADH1, affecting approximately 12,000 people in the U.S. The company will also present data on infigratinib for children with achondroplasia and a gene therapy candidate for Congenital Adrenal Hyperplasia (CAH).
BridgeBio Pharma (Nasdaq: BBIO) has announced the dosing of the first patient in a Phase 2 trial for BBP-418, an oral treatment for LGMD2i, a serious genetic muscle disorder. This investigational therapy received Orphan Drug Designation from the FDA and EMA due to its potential to address a critical unmet medical need. The trial aims to enroll up to 16 patients, focusing on safety and key efficacy indicators such as muscle glycosylation and functional measures. The progress in this trial represents a significant step towards developing effective therapies for LGMD2i patients.
BridgeBio Pharma announced a secondary public offering of 3,000,000 shares of common stock at $62.50 per share, sold by KKR Genetic Disorder L.P. The underwriters have a 30-day option to purchase up to 450,000 additional shares. The offering is set to close on February 17, 2021. The company will not receive any proceeds from the offering as all shares are sold by the stockholder. Goldman Sachs is the book-running manager for the deal. The offering is conducted under an automatic shelf registration statement with the SEC.
BridgeBio Pharma announced a secondary public offering of 3,000,000 shares of its common stock by KKR Genetic Disorder L.P. The underwriters have a 30-day option to purchase an additional 450,000 shares. All shares are sold by the stockholder, with BridgeBio not receiving any proceeds. The offering is part of a previously filed automatic shelf registration statement with the SEC. Goldman Sachs is the book-running manager, supported by KKR Capital Markets and Raymond James. This release does not constitute an offer or solicitation to buy the securities.
BridgeBio Pharma (Nasdaq: BBIO) announced on February 1, 2021, that its compensation committee granted 16,772 restricted stock units to 11 new employees. These awards were made under the 2019 Inducement Equity Plan, adhering to Nasdaq Listing Rule 5635(c)(4). BridgeBio, founded in 2015, focuses on developing transformative medicines for genetic diseases, with over 20 programs in its pipeline targeting Mendelian diseases and genetically driven cancers.
BridgeBio Pharma (BBIO) has completed the acquisition of Eidos Therapeutics, strengthening its clinical and commercial capabilities. This merger, approved by stockholders, focuses on acoramidis, a therapy targeting transthyretin amyloidosis (ATTR), which impacts over 400,000 people globally. BridgeBio anticipates significant data releases for its core programs in 2021 and 2022, with plans to launch two drugs if approved. Eidos shareholders can receive either 1.85 BBIO shares or $73.26 in cash for each Eidos share.
BridgeBio Pharma announced the pricing of $650 million of 2.25% convertible senior notes due 2029, up from a previously planned $400 million. The offering includes an option for initial purchasers to buy an additional $97.5 million in notes, with closing expected on January 28, 2021. These unsecured notes will bear interest at 2.25% annually and have a conversion price of approximately $97.04 per share, representing a 47.5% premium over the January 25 closing price of $65.79. Net proceeds are intended for general corporate purposes, including share repurchases and research funding.
BridgeBio Pharma (Nasdaq: BBIO) announced its plans to offer $400 million in convertible senior notes due 2029, potentially increasing by another $60 million through initial purchasers. The notes will be senior unsecured obligations, bearing interest semi-annually, with specific conversion conditions. Proceeds will fund capped call transactions, share repurchases up to $50 million, and general corporate purposes, including R&D and clinical development. However, the company will not redeem the notes before February 2026, and potential market reactions from related derivative transactions could impact stock prices.
BridgeBio Pharma and Eidos Therapeutics announced that their stockholders approved the acquisition of Eidos by BridgeBio. The merger, expected to close around January 26, 2021, allows Eidos shareholders to choose between receiving 1.85 shares of BridgeBio or $73.26 in cash for each share of Eidos. The cash consideration will be capped at $175 million and prorated if necessary. Both companies aim to leverage Eidos's investigational therapy, acoramidis, targeting transthyretin amyloidosis to enhance value for patients and investors.
BridgeBio Pharma (Nasdaq: BBIO) is set to acquire Eidos Therapeutics (Nasdaq: EIDX) with a transaction expected to close around January 26, 2021. This acquisition is subject to stockholder approvals during special meetings scheduled for January 19, 2021. Eidos shareholders can choose to receive either 1.85 shares of BridgeBio's stock or $73.26 in cash for each Eidos share they own, with the cash portion capped at $175 million. Proxy advisory firms recommend voting in favor of the merger.